Iterion Therapeutics Strengthens Board with Additions of Manuel Aivado, MD, PhD and Bob Smith

Summary

Iterion Therapeutics announced the addition of two new independent board members, Manuel Aivado, MD, PhD and Bob Smith. The clinical-stage oncology company focuses on developing first-in-class therapies targeting aberrant Wnt/β-catenin signaling.